Moderna already has messenger RNA-based cancer vaccines in clinical development, but it wants to see if the T cell technology of immunotherapy developer Immatics can give its efforts a boost and it’s paying the biotech $120 million to begin a collaboration.

Moderna在临床开发中已经拥有基于信使RNA的癌症疫苗，但它希望看看免疫疗法开发者Immatics的T细胞技术是否可以加大力度，并支付生物技术1.2亿美元开始合作。

In addition to the upfront payment, the deal announced Monday calls for Moderna to provide its new partner with research funding for the multi-drug alliance. Milestone payments to Tubingen, Germany-based Immatics could top $1.7 billion.

除了预付款外，该协议周一宣布要求Moderna为其新合作伙伴提供多药物联盟的研究经费。德国Tubingen Immatics的里程碑付款可能高达17亿美元。

Though Cambridge, Massachusetts-based Moderna might be best known for its mRNA Covid-19 vaccine Spikevax, cancer vaccines were one of the company’s initial areas of focus. Moderna makes these vaccines by designing mRNA that gets a cell’s protein-making machinery to produce an antigen that prompts an immune response to cancer.

虽然位于马萨诸塞州剑桥的Moderna可能以其mRNA Covid-19疫苗Spikevax而闻名，但癌症疫苗是该公司最初关注的领域之一。Moderna通过设计mRNA来制造这些疫苗，该mRNA使细胞的蛋白质制造机器产生促进对癌症的免疫应答的抗原。

Meanwhile, Immatics develops bispecific T cell receptor therapies (TCERs) that redirect immune cells to address cancer. The collaboration will span various modalities including bispecific TCERs, cell therapies, and cancer vaccines..

同时，未成熟发展双特异性T细胞受体疗法（TCERs），重定向免疫细胞解决癌症。合作将涵盖各种形式，包括双特异性TCER，细胞疗法和癌症疫苗。。

The partners aim to apply Moderna’s mRNA technology toward the in vivo expression of Immatics’s next-generation TCERs, which have an extended half-life. The alliance will also discover new mRNA-based cancer vaccines leveraging technologies from both companies. Under the deal terms, Moderna will lead clinical development and commercialization of cancer vaccines and TCER therapies that are produced under the collaboration.

合作伙伴的目标是将Moderna的mRNA技术应用于未成熟的下一代TCER的体内表达，其具有延长的半衰期。该联盟还将利用两家公司的技术发现新的基于mRNA的癌症疫苗。根据协议条款，Moderna将领导在合作下生产的癌症疫苗和TCER疗法的临床开发和商业化。

Moderna will also take the lead in commercializing them if they’re approved..

如果获得批准，Moderna还将率先将其商业化。。

The third component of the alliance will evaluate Immatics’s IMA203, a T cell receptor engineered T cell that addresses a target called PRAME, in combination with Moderna’s mRNA-based cancer vaccine for that same target. Immatics is responsible for the preclinical research and Phase 1 testing of this combination.

联盟的第三个组成部分将评估Immatics的IMA203，这是一种T细胞受体工程化的T细胞，可以解决称为PRAME的目标，并结合Moderna基于mRNA的癌症疫苗用于同一目标。Immatics负责该组合的临床前研究和1期测试。

Each company retains full ownership of its PRAME therapeutic. Costs of clinical development of the experimental combination treatment will be shared..

每家公司均保留其PRAME therapeutic的完全所有权。将分担实验性联合治疗的临床开发费用。。

Immatics could earn $1.7 billion in milestone payments as well as royalties from sales of approved TCER products and certain vaccines commercialized under the collaboration agreement. The deal gives Immatics an option to share in the collaboration of the most advanced TCER.

Immatics可以获得17亿美元的里程碑付款以及销售经批准的TCER产品和根据合作协议商业化的某些疫苗的版税。该协议使Immatics可以选择与最先进的TCER合作分享。

“We believe Immatics’s cancer target and TCR platforms, along with Moderna’s cutting-edge mRNA technology, represent a powerful combination that has the potential to deliver meaningful benefits to cancer patients,” Immatics Chief Innovation Officer Toni Weinschenk said in a prepared statement.

Immatics首席创新官Toni Weinschenk在准备好的声明中说：“我们相信Immatics的癌症靶点和TCR平台以及Moderna尖端的mRNA技术代表了一种强大的组合，有可能为癌症患者带来有意义的益处。”。

The new collaboration expands the partnership lists of both companies. Moderna has been researching cancer vaccines under an alliance with Merck. The cancer mRNA-4157 program, a personalized vaccine made from neoantigens that come from the patient, is in late-stage clinical development. Research costs for this program are split equally between Moderna and Merck.

新合作扩大了两家公司的合作伙伴名单。Moderna一直在与默克合作研究癌症疫苗。癌症mRNA-4157程序是一种由来自患者的新抗原制成的个性化疫苗，处于晚期临床开发阶段。Moderna和默克公司的研究成本平均分配。

Immatics currently has strategic partnerships with Bristol Myers Squibb and Genmab..

Immatics目前与Bristol-Myers Squibb和Genmab拥有战略合作伙伴关系。。

Photo: Adam Glanzman/Bloomberg, via Getty Images

照片：Adam Glanzman/Bloomberg，通过Getty图片

Promoted

促进

Payer’s Place: Carrie Kincaid

付款人的地方：Carrie Kincaid

Carrie Kincaid, Senior Vice President, Market Development at Priority Health discusses how Priority Health is addressing the gaps in rural healthcare.

优先卫生市场发展高级副总裁Carrie Kincaid讨论了优先卫生如何解决农村医疗保健方面的差距。

HLTH and MedCity News

HLTH和MedCity新闻

Promoted

促进

Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems

导航医疗保健数据革命：卫生系统的优先事项，机遇和挑战

Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.

Arcadia最近与HIMSS市场洞察力合作，调查高管，IT，技术和临床领导者。这是我们发现的。

Michael Meucci, President and CEO, Arcadia

Michael Meucci，Arcadia总裁兼首席执行官

Payer’s Place: Carrie Kincaid

付款人的地方：Carrie Kincaid

Carrie Kincaid, Senior Vice President, Market Development at Priority Health discusses how Priority Health is addressing the gaps in rural healthcare.

优先卫生市场发展高级副总裁Carrie Kincaid讨论了优先卫生如何解决农村医疗保健方面的差距。

HLTH and MedCity News

HLTH和MedCity新闻

Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems

导航医疗保健数据革命：卫生系统的优先事项，机遇和挑战

Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.

Arcadia最近与HIMSS市场洞察力合作，调查高管，IT，技术和临床领导者。这是我们发现的。

Michael Meucci, President and CEO, Arcadia

Michael Meucci，Arcadia总裁兼首席执行官